| Literature DB >> 30666922 |
Roopa Govindaraju1, Roopa Karki2, Jayanthi Chandrashekarappa1, Mukunthan Santhanam1, Akshay K K Shankar1, Hanumanthachar K Joshi1, Goli Divakar2.
Abstract
BACKGROUND: TheEntities:
Keywords: Bioavailability; curcumin; ionotropic gelation; nanoparticles; polysorbate 80; sodium alginate.
Mesh:
Substances:
Year: 2019 PMID: 30666922 PMCID: PMC6691850 DOI: 10.2174/2211738507666190122121242
Source DB: PubMed Journal: Pharm Nanotechnol ISSN: 2211-7385
Formulations of curcumin loaded alginate-polysorbate 80 nanoparticles using ionotropic gelation by 32 factorial design.
|
|
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| |
| Curcumin (mg) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Sodium alginate (mg) |
|
|
|
|
|
|
|
|
|
| Polysorbate 80 (mg) | 10 | 20 | 40 | 10 | 20 | 40 | 10 | 20 | 40 |
| Methyl paraben (mg) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Calcium chloride (mg) |
|
|
|
|
|
|
|
|
|
Data for the characterization of curcumin loaded sodium alginate nanoparticles.
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|
| Physical | <1 | <1 | <1 | 4 | 6 | 6 | 8 | 9 | 11 |
| % Drug loading | 6.1 | 6.2 | 6.0 | 6.2 | 6.2 | 6.3 | 6.1 | 6.3 | 6.2 |
| %Encapsulation Efficiency mean ± S.D | 92±5.2 | 94±4.3 | 91±3.1 | 94±4.2 | 93±2.9 | 95±4.5 | 92 ±3.6 | 95±4.6 | 93 ±2.5 |
| Mean particle | NE | NE | NE | 105±3.0 | 292±0.40 | 380±6.15 | 107±3.15 | 285±5.15 | 383±7.10 |
| Zeta potential | NE | NE | NE | 150±1.15 | 150 ±1.15 | 200 ±2.15 | 200 ±2.15 | 200 ±2.15 | 200 ±2.15 |
| %CDR SGF 2hours | NE | NE | NE | 1.5±0.100 | 1.7±0.110 | 1.5±0. 100 | 1.60 ±0.017 | 1.5±0.100 | 1.7±0.110 |
| %CDR SIF 6hours | NE | NE | NE | 2.9±0.120 | 2.6±0.110 | 28±0.130 | 2.4±0.101 | 2.6±0.110 | 2.6±0.110 |
| % CDR SCF 24 hours | NE | NE | NE | 95±0.16 | 97±0.19 | 94 ±0.92 | 95 ±0.16 | 96 ±0.17 | 94±0.18 |
NE - Not evaluated
*Number of days of no settling in Nanosuspension: n=3.
Biochemical characteristics (mean ± SD) of the participants on medical examinations.
|
|
|
|
|
|---|---|---|---|
| 1) | Age (Years) | - | 25 ± 3 |
| 2) | Body Height (m) | - | 1.76 ± 0.03 |
| 3) | Body weight (Kg) | - | 70 ± 6.1 |
| 4) | BMI (Kg/m2) | <25 | 23.8 ± 1.8 |
| 5) | Total Cholesterol (mg/dL) | 0-200 | 105 ± 30.1 |
| 6) | LDL Cholesterol (mg/dL) | 0-150 | 120 ± 7.6 |
| 7) | HDL Cholesterol (mg/dL) | 40-70 | 58 ± 9.2 |
| 8) | Triacylglycerols (mg/dL) | 0-200 | 128 ± 25 |
| 9) | Fasting Plasma glucose (mg/dL) | 70-110 | 95 ± 6 |
| 10) | Haematocrit (%) | 40-45 | 42 ± 0.2 |
| 11) | Blood Hb (g/dL) | 13-17 | 14.5 ± 2.1 |
| 12) | Systolic Blood Pressure (mmHg) | 120 | 120 ± 2 |
| 13) | Diastolic Blood Pressure (mmHg) | 80 | 80 ± 2 |
Data for the plasma concentration time profiles of curcumin suspension and nanosuspension in human volunteers.
|
|
| |
|---|---|---|
|
|
| |
| 0 | 46 ± 14 | 47 ± 12 |
| 1 | 58 ± 14 | 566 ± 132 |
| 2 | 75 ± 15 | 637 ± 122 |
| 4 | 87 ± 17 | 531 ± 82 |
| 6 | 68 ± 26 | 433 ± 151 |
| 8 | 55 ± 23 | 331 ± 126 |
| 24 | 45± 18 | 70 ± 26 |
Values are mean of 3 volunteers (n=6).
Data of log plasma concentration vs. time of curcumin suspension and nanosuspension.
|
|
| |
|---|---|---|
|
|
| |
| 0 | 1.7 | 1.7 |
| 1 | 1.8 | 2.8 |
| 2 | 1.9 | 2.8 |
| 4 | 1.9 | 2.7 |
| 6 | 1.8 | 2.6 |
| 8 | 1.7 | 2.5 |
| 24 | 1.7 | 1.8 |
Pharmacokinetic parameters of curcumin suspension and nanosuspension.
|
|
|
|
|---|---|---|
|
| 87.7 ± 17.9 | 636 ± 122 |
|
| 4 | 2 |
|
| 6.01 | 6.01 |
|
| 0.115 | 0.115 |
|
| 1360 ± 18.4 | 7021± 92.7 |